The situations aren't as disimilar as you indicate. Stock price so low that they CAN'T raise enough capital to stay liquid. Board of directors in managements pocket. Etc.
Your implied odds analogy doesn't work because it doesn't incorporate the cost of dilution to common shareholders.
Yep... in respect to other indications for Atryn such as AD, burn therapy, DIC, DVT, etc., is it correct to say the essential product that's being produced will be unchanged for all indications except for dosing and means of application? If that's true, then wouldn't the entire body of testing results be available for FDA applications? If so, would the FDA require the same level of testing for each indication that it would for an unknown drug? Tia.
as the (3) major partners... given their involvement w/ drugs in the GTC pipeline.
Merrimack PharmAthene Progenetics
call 'em what you wish... but the drugs (although not necessarily of lesser importance / value) they are developing in collaboration w/ GTC are not in the GTC pipeline per se.
regards JL
... so on Sep 18th 2010, if all continues to come together... GTCB will have a market cap of ???
Market Data 
Markets 
AI
